Posted by Michael Wonder on 08 Apr 2025
Datroway approved in the EU for patients with previously treated metastatic HR positive, HER2 negative breast cancer
8 April 2025 - Second DXd antibody drug conjugate approved in EU based on Daiichi Sankyo’s DXd technology
Datroway (datopotamab deruxtecan) has been approved in the European Union for the treatment of adult patients with unresectable or metastatic hormone receptor positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting.
